A 52-week, randomized, double-blind, parallel-group study of fluticasone propionate/salmeterol DISKUS combination product (FSC) 250/50 mcg BID and fluticasone propionate (FP) DISKUS 250 mcg BID in treatment of subjects with asthma.
Latest Information Update: 05 Sep 2023
At a glance
- Drugs Salmeterol/fluticasone propionate (Primary) ; Fluticasone propionate
- Indications Asthma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 27 Dec 2016 New source identified and integrated (European Clinical Trials Database record; EudraCT2015-004892-61).
- 14 May 2010 Results presented at 106th International Conference of the American Thoracic Society.
- 02 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.